Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Wei Zhou(National Institutes of Pharmaceutical Research and Development (China)), Jingkang Shen(Shanghai Institute of Materia Medica)
Molecular Cancer Therapeutics
May 17, 2023
Cited by 41


Related Papers